Mabthera

What it is used for

Non-Hodgkin’s Lymphoma: MABTHERA is indicated for treatment of patients with: CD20 positive, previously untreated, Stage III/IV follicular, B-cell non-Hodgkin’s lymphoma. CD20 positive, relapsed or refractory low grade or follicular, B-cell non-Hodgkin’s lymphoma, CD20 positive, diffuse large B-cell non-Hodgkin’s lymphoma, in combination with chemotherapy. Chronic Lymphocytic Leukaemia: MABTHERA is indicated for the treatment of patients with CD20 positive chronic lymphocytic leukaemia (CLL) in combination with chemotherapy. Rheumatoid Arthritis: MABTHERA (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with severe, active rheumatoid arthritis who have had an inadequate response or intolerance to at least one tumour necrosis factor (TNF) inhibitor therapy. MABTHERA has been shown to reduce the rate of progression of joint damage as measured by x-ray when given in combination with methotrexate. Granulomatosis with polyangiitis (Wegener’s ) (GPA) and Microscopic polyangiitis (MPA). MABTHERA in combination with glucocorticoids is indicated for the induction of remission in patients with severely active Granulomatosis with polyangiitis (GPA, also known as Wegener’s granulomatosis) and Microscopic polyangiitis (MPA). The efficacy and safety of retreatment with MABTHERA have not been established.